Global Artificial Blood Market Size, Status and Forecast 2019-2025
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Artificial Blood Quarterly Market Size Analysis
- 2.1 Artificial Blood Business Impact Assessment - COVID-19
- 2.1.1 Global Artificial Blood Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Artificial Blood Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 By Players, Global Artificial Blood Quarterly Market Size, 2019 VS 2020
- 3.2 By Players, Artificial Blood Headquarters and Area Served
- 3.3 Date of Key Players Enter into Artificial Blood Market
- 3.4 Key Players Artificial Blood Product Offered
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Artificial Blood Segments, By Type
- 4.1 Introduction
- 1.4.1 Human Blood
- 1.4.2 Synthetic Blood
- 1.4.3 Animal Blood
- 4.2 By Type, Global Artificial Blood Market Size, 2019-2021
5 Impact of Covid-19 on Artificial Blood Segments, By Application
- 5.1 Overview
- 5.5.1 Hemoglobin-Based Oxygen Carriers (HBOCs)
- 5.5.2 Perflurocarbon Emulsions (PFCEs)
- 5.2 By Application, Global Artificial Blood Market Size, 2019-2021
- 5.2.1 By Application, Global Artificial Blood Market Size by Application, 2019-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 Dextro-Sang Corporation
- 7.1.1 Dextro-Sang Corporation Business Overview
- 7.1.2 Dextro-Sang Corporation Artificial Blood Quarterly Revenue, 2020
- 7.1.3 Dextro-Sang Corporation Artificial Blood Product Introduction
- 7.1.4 Dextro-Sang Corporation Response to COVID-19 and Related Developments
- 7.2 BioPure Corporation
- 7.2.1 BioPure Corporation Business Overview
- 7.2.2 BioPure Corporation Artificial Blood Quarterly Revenue, 2020
- 7.2.3 BioPure Corporation Artificial Blood Product Introduction
- 7.2.4 BioPure Corporation Response to COVID-19 and Related Developments
- 7.3 Sangart
- 7.3.1 Sangart Business Overview
- 7.3.2 Sangart Artificial Blood Quarterly Revenue, 2020
- 7.3.3 Sangart Artificial Blood Product Introduction
- 7.3.4 Sangart Response to COVID-19 and Related Developments
- 7.4 Northfield Laboratories
- 7.4.1 Northfield Laboratories Business Overview
- 7.4.2 Northfield Laboratories Artificial Blood Quarterly Revenue, 2020
- 7.4.3 Northfield Laboratories Artificial Blood Product Introduction
- 7.4.4 Northfield Laboratories Response to COVID-19 and Related Developments
- 7.5 Baxter International
- 7.5.1 Baxter International Business Overview
- 7.5.2 Baxter International Artificial Blood Quarterly Revenue, 2020
- 7.5.3 Baxter International Artificial Blood Product Introduction
- 7.5.4 Baxter International Response to COVID-19 and Related Developments
- 7.6 Dentritech
- 7.6.1 Dentritech Business Overview
- 7.6.2 Dentritech Artificial Blood Quarterly Revenue, 2020
- 7.6.3 Dentritech Artificial Blood Product Introduction
- 7.6.4 Dentritech Response to COVID-19 and Related Developments
- 7.7 FluorO2 Therapeutics
- 7.7.1 FluorO2 Therapeutics Business Overview
- 7.7.2 FluorO2 Therapeutics Artificial Blood Quarterly Revenue, 2020
- 7.7.3 FluorO2 Therapeutics Artificial Blood Product Introduction
- 7.7.4 FluorO2 Therapeutics Response to COVID-19 and Related Developments
- 7.8 Nuvox Pharma
- 7.8.1 Nuvox Pharma Business Overview
- 7.8.2 Nuvox Pharma Artificial Blood Quarterly Revenue, 2020
- 7.8.3 Nuvox Pharma Artificial Blood Product Introduction
- 7.8.4 Nuvox Pharma Response to COVID-19 and Related Developments
- 7.9 Alpha Therapeutic Corporation
- 7.9.1 Alpha Therapeutic Corporation Business Overview
- 7.9.2 Alpha Therapeutic Corporation Artificial Blood Quarterly Revenue, 2020
- 7.9.3 Alpha Therapeutic Corporation Artificial Blood Product Introduction
- 7.9.4 Alpha Therapeutic Corporation Response to COVID-19 and Related Developments
- 7.10 HemoBioTech
- 7.10.1 HemoBioTech Business Overview
- 7.10.2 HemoBioTech Artificial Blood Quarterly Revenue, 2020
- 7.10.3 HemoBioTech Artificial Blood Product Introduction
- 7.10.4 HemoBioTech Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
- 9.1 About US
This report covers market size and forecasts of Artificial Blood, including the following market information:
Global Artificial Blood Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Artificial Blood Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Artificial Blood Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Artificial Blood Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Dextro-Sang Corporation, BioPure Corporation, Sangart, Northfield Laboratories, Baxter International, Dentritech, FluorO2 Therapeutics, Nuvox Pharma, Alpha Therapeutic Corporation, HemoBioTech, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Human Blood
Synthetic Blood
Animal Blood
Based on the Application:
Hemoglobin-Based Oxygen Carriers (HBOCs)
Perflurocarbon Emulsions (PFCEs)